KRAS and non-small cell lung carcinoma: In metastatic colorectal cancer, mutations of K-Ras have an adverse effect on response to anti-EGFR antibody and cetuximab [134]; also, in NSCLC, mutations in K-Ras affect resistance to treatment with gefitinib or erlotinib drugs [135].